Who
Patricia L. Allen
Director
Company insider
Files Form 4 as: Director, Zenas BioPharma; Director, Deciphera Pharmaceuticals; Director, Yumanity Therapeutics; Chief Financial Officer, Larimar Therapeutics; VP of Finance and Treasurer, Alnylam Pharmaceuticals.
In numbers
- Trades disclosed
- 116
- Buys
- 4
- Sells
- 6
- Bought
- $1.0M
- Sold
- $3.4M
- Companies
- 5
- Companies where not an officer
- 3
- First trade
- 14 Dec 2006
- Last trade
- 15 Jun 2026
- Last filed
- 17 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Jun 2026filed 17 Jun 2026 | ZBIO Zenas BioPharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,500 at $0.00 | filing |
| 15 Jun 2026filed 17 Jun 2026 | ZBIO Zenas BioPharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,500 at $0.00 | filing |
| 13 Feb 2026filed 13 Feb 2026 | ZBIO Zenas BioPharmaBiotechnology | SEC FORM 4 Bought | $110K4,160 at $26.36 | filing |
| 13 Feb 2026filed 13 Feb 2026 | ZBIO Zenas BioPharmaBiotechnology | SEC FORM 4 Bought | $110K4,160 at $26.36 | filing |
| 12 Feb 2026filed 13 Feb 2026 | ZBIO Zenas BioPharmaBiotechnology | SEC FORM 4 Bought | $119K5,000 at $23.77 | filing |
| 12 Feb 2026filed 13 Feb 2026 | ZBIO Zenas BioPharmaBiotechnology | SEC FORM 4 Bought | $139K5,700 at $24.34 | filing |
| 12 Feb 2026filed 13 Feb 2026 | ZBIO Zenas BioPharmaBiotechnology | SEC FORM 4 Bought | $133K5,000 at $26.50 | filing |
| 12 Feb 2026filed 13 Feb 2026 | ZBIO Zenas BioPharmaBiotechnology | SEC FORM 4 Bought | $119K5,000 at $23.77 | filing |
| 12 Feb 2026filed 13 Feb 2026 | ZBIO Zenas BioPharmaBiotechnology | SEC FORM 4 Bought | $139K5,700 at $24.34 | filing |
| 12 Feb 2026filed 13 Feb 2026 | ZBIO Zenas BioPharmaBiotechnology | SEC FORM 4 Bought | $133K5,000 at $26.50 | filing |
| 10 Jun 2025filed 12 Jun 2025 | ZBIO Zenas BioPharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,500 at $0.00 | filing |
| 12 Sep 2024filed 16 Sep 2024 | ZBIO Zenas BioPharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,500 at $0.00 | filing |
| 11 Jun 2024filed 11 Jun 2024 | Deciphera Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —10,233 | filing |
| 11 Jun 2024filed 11 Jun 2024 | Deciphera Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —7,181 | filing |
| 11 Jun 2024filed 11 Jun 2024 | Deciphera Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —12,000 | filing |
| 11 Jun 2024filed 11 Jun 2024 | Deciphera Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —9,570 | filing |
| 11 Jun 2024filed 11 Jun 2024 | Deciphera Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —18,500 | filing |
| 11 Jun 2024filed 11 Jun 2024 | Deciphera Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —3,269 | filing |
| 11 Jun 2024filed 11 Jun 2024 | Deciphera Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —30,000 | filing |
| 11 Jun 2024filed 11 Jun 2024 | Deciphera Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —4,727 | filing |
News
Head to Head Review: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) versus Zenas BioPharma (NASDAQ:ZBIO)ZBIO · themarketsdaily.com · 18 Oct 2026Head-To-Head Contrast: Zenas BioPharma (NASDAQ:ZBIO) and MacroGenics (NASDAQ:MGNX)ZBIO · themarketsdaily.com · 14 Oct 2026
0 headlines in the last 90 days name Patricia L. Allen; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.